Andrea Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrea Harris has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Ishwarlal Jialal
University of Texas Southwestern Medical Center
1 shared publicationSridevi Devaraj
University of Texas Southwestern Medical Center
1 shared publication
Latest Publications
- 1 September 2002
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 4 (5) , 373-380
Oxidative stress, alpha-tocopherol therapy, and atherosclerosis
Atherosclerosis is the leading cause of morbidity and mortality in the United States. Evidence suggests that antioxidants, especially α-tocopherol (AT), have potential benefits with respect to cardiovascular disease. AT has been shown to decrease lipid peroxidation, to inhibit platelet adhesion, aggregation, and smooth muscle cell proliferation, to exert anti-inflammatory effects on monocytes, and to improve endothelial function. Low levels of AT are related to a higher incidence of cardiovascular disease and increased intakes appear to afford protection against cardiovascular disease. Although clinical trials with AT supplementation to date have been conflicting, the majority of evidence supports a benefit for AT supplementation in patients with pre-existing cardiovascular disease. Clearly, more clinical trials are required in individuals with increased oxidative stress before a definitive recommendation can be made with respect to AT supplementation in atherosclerosis.
- 1 September 2002
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 4 (5) , 373-380
Oxidative stress, alpha-tocopherol therapy, and atherosclerosis
Atherosclerosis is the leading cause of morbidity and mortality in the United States. Evidence suggests that antioxidants, especially α-tocopherol (AT), have potential benefits with respect to cardiovascular disease. AT has been shown to decrease lipid peroxidation, to inhibit platelet adhesion, aggregation, and smooth muscle cell proliferation, to exert anti-inflammatory effects on monocytes, and to improve endothelial function. Low levels of AT are related to a higher incidence of cardiovascular disease and increased intakes appear to afford protection against cardiovascular disease. Although clinical trials with AT supplementation to date have been conflicting, the majority of evidence supports a benefit for AT supplementation in patients with pre-existing cardiovascular disease. Clearly, more clinical trials are required in individuals with increased oxidative stress before a definitive recommendation can be made with respect to AT supplementation in atherosclerosis.